Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7065794

Thyroid function screening in new psychiatric admissions.

J E Morley·R B Shafer
View original source ↗Export metadata ↓

Abstract

Thyroid function screening may be of value in psychiatric patients. The present study was undertaken to determine the incidence of thyroid abnormalities in psychiatric patients during short-term admissions. Results of thyroid function tests disclosed an elevated free thyroxine index (FT4I) and free triiodothyronine index (FT3I) in 19% of 386 psychiatric patients during short-term admissions to Minneapolis Veterans Administration Medical Center. Elevated test results were particularly common in paranoid schizophrenics (38%) and in patients with amphetamine abuse (32%). On retesting, at two to three weeks after hospitalization, the FT4I and FT3I had returned to normal in 13 of 16 and 17 of 17 patients, respectively. Undiagnosed hypothyroidism was found in four patients with a diagnosis of manic-depressive psychosis on hospital admission. Serial sampling needs to be undertaken to assess the most appropriate time for thyroid function testing after short-term psychiatric admission.

Explore related subjects

AmphetaminesBipolar DisorderFemaleHumansHyperthyroidismHypothyroidismMaleMass ScreeningMental DisordersSchizophrenia, ParanoidSubstance-Related DisordersThyroid DiseasesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J E Morley, R B Shafer. 1982. Thyroid function screening in new psychiatric admissions.. https://pubmed.ncbi.nlm.nih.gov/7065794/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

New insights into the mechanism of action of amphetamines.

Amphetamine is a psychostimulant commonly used to treat several disorders, including attention deficit, narcolepsy, and obesity. Plasmalemmal and vesicular monoamine transporters, such as the neuronal dopamine transporter and the vesicular monoamine transporter-2, are two of its principal targets. This review focuses on new insights, obtained from both in vivo and in vitro studies, into the molecular mechanisms whereby amphetamine, and the closely related compounds methamphetamine and methylenedioxymethamphetamine, cause monoamine, and particularly dopamine, release. These mechanisms include amphetamine-induced exchange diffusion, reverse transport, and channel-like transport phenomena as well as the weak base properties of amphetamine. Additionally, amphetamine analogs may affect monoamine transporters through phosphorylation, transporter trafficking, and the production of reactive oxygen and nitrogen species. All of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases.

Amphetamines↗
PubMed2006

Effect of GABAergic ligands on the anxiolytic-like activity of DOI (a 5-HT(2A/2C) agonist) in the four-plate test in mice.

5-HTergic and GABAergic systems are involved in neurobiology of anxiety. Precedent studies have demonstrated that SSRIs possessed an anxiolytic-like effect in the four-plate test (FPT) at doses that did not modify spontaneous locomotor activity. This effect seems to be mediated through the activation of 5-HT(2A) postsynaptic receptors. The purpose of the present study was to examine the implication of GABA system in the anxiolytic-like activity of DOI in the FPT. To achieve this, the co-administration of DOI (5-HT(2A/2C) receptor agonists) with GABA(A) and GABA(B) receptor ligands was evaluated in the FPT. Alprazolam, diazepam and muscimol (for higher dose) potentiated the anxiolytic-like effect of DOI. Bicuculline, picrotoxin and baclofen inhibited the anxiolytic-like effect of DOI. Flumazenil and CGP 35348 had no effect on the anxiolytic-like activity of DOI. These results suggest that the GABA system seems to be strongly implicated in the anxiolytic-like activity of DOI in the FPT.

Amphetamines↗